C4 Therapeuticsincis A Clinical Stage Biopharmaceutical Company Based In Watertownmassachusettsthe Company Focuses On Developing Innovative Therapies For Cancer Treatment And Is Listed On The Nasdaq Under The Ticker Symbol Cccc C4 Therapeutics Specializes In Targeted Protein Degradation Through Its Proprietary Platformtorpedotarget Oriented Protein Degrader Optimizer This Platform Enables The Creation Of Small Molecule Medicines That Degrade Disease Causing Proteins By Utilizing The Body S Natural Protein Recycling Systemthe Company S Lead Productcemsidomideis An Oral Monodac Degrader Targeting Ikzf1 And Ikzf3 Proteinsaimed At Treating Multiple Myeloma And Non Hodgkinae S Lymphomaother Products In Development Include Cft1946 For V600 Mutant Cancers And Cft8919 For Non Small Cell Lung Canceralong With Additional Undisclosed Cancer Treatment Programs C4 Therapeutics Collaborates With Major Pharmaceutical Companies Such As Rochebiogenbetta Pharmaceuticalsmerckand Merck Kgaaemphasizing Its Commitment To Advancing Cancer Research And Development Through Strategic Partnerships
